Q: What Is Rezon Bio's Batch Success Rate And Regulatory Audit Track Record?

Reliable biologics manufacturing depends on more than capacity. It requires consistent batch performance, inspection readiness, regulatory fluency, and quality systems that can support a program as it moves from clinical development into commercial supply. Rezon Bio brings these elements together through a 97% batch success rate since 2024, experience with major global health authorities, and two GMP facilities operating under a unified quality management system. Its Gdańsk site supports clinical manufacturing, while the FDA-approved Warsaw-Duchnice facility is built for late-phase and commercial production. Together, these capabilities help sponsors reduce operational risk, maintain supply continuity, and navigate complex regulatory expectations with greater confidence.

Access the full Q&A to see how Rezon Bio supports biologics programs through each stage of development and commercialization.